What Is the Opioid Crisis? Analyzing Its Causes and Effects

In December 1995, the Food and Drug Administration approved OxyContin - a new extended-release formulation of oxycodone manufactured by Purdue Pharma.

The company's leadership believed they had a genuine therapeutic innovation: a long-acting opioid that could provide steady pain relief without the peaks and troughs that drove abuse of shorter-acting formulations.

The extended-release design, they argued internally and then to physicians, meant the drug delivered opioid more slowly, reducing the euphoric rush that produced addiction.

It was a compelling story. It was also, as subsequent litigation would establish through millions of pages of internal documents, not well supported by the evidence the company possessed.

Purdue deployed an unusually large and aggressive sales force - some 600 representatives at launch, eventually growing to over 1,000 - who visited physicians with a message that Purdue's own documents would later reveal was deliberately calibrated to minimize addiction concerns.

The company's representatives cited a letter published in the New England Journal of Medicine in 1980 - a five-sentence letter, not a study, written by Dr. Hershel Jick and Jane Porter - which had noted that among hospitalized patients given narcotic medications, addiction was rare.

This observation about inpatients receiving opioids under close supervision was transmuted, through Purdue's marketing, into a general claim that opioid addiction occurred in fewer than one percent of patients.

The American Pain Society's campaign to recognize pain as the "fifth vital sign" - which had received Purdue funding - created institutional pressure on physicians to treat pain more aggressively, and OxyContin was there to meet it.

The results were catastrophic in a way that unfolded slowly enough to be normalized. Prescription opioid overdose deaths rose from around 4,000 in 1999 to over 17,000 in 2010. By then the United States was consuming more than 80 percent of the global supply of oxycodone despite containing less than 5 percent of the world's population.

Richard Sackler, who served as Purdue's president and later as board co-chair, had written in a 2001 email that when the overdose problem attracted attention, the response should be to "hammer on the abusers in every way possible" - framing addiction as a moral failure of patients rather than a consequence of the company's marketing strategy.

The Sackler family, whose fortune had been built on pharmaceutical marketing innovations pioneered by patriarch Arthur Sackler in the 1950s, eventually paid settlements later approved at approximately $7.4 billion (the pledged amount, distinct from funds actually distributed), while the company itself filed for bankruptcy in 2019 under the weight of more than 3,000 civil lawsuits from states, counties, and tribes.

Many patients who were prescribed opioids for legitimate pain became dependent, were cut off from medication when the prescribing environment changed, and then turned to heroin and fentanyl to survive withdrawal. Journalists and researchers covering the crisis, including Patrick Radden Keefe in Empire of Pain (2021), have argued the outcome reflected systemic decisions by manufacturers and distributors as much as individual choices.

Key Definitions

Opioid - A class of drugs that act on opioid receptors in the brain and body. Opioids include natural compounds derived from the opium poppy (morphine, codeine), semi-synthetic compounds (oxycodone, hydrocodone, heroin), and fully synthetic compounds (fentanyl, methadone, tramadol).

All opioids share the ability to relieve pain, produce euphoria at sufficient doses, cause physical dependence, and suppress respiration - which is the mechanism of opioid overdose death.

Opioid use disorder (OUD) - The clinical term for addiction to opioids, defined in the DSM-5 by a pattern of compulsive opioid use, loss of control, craving, and continued use despite significant negative consequences.

OUD involves both neurobiological changes (altered reward circuitry, prefrontal dysfunction) and behavioral patterns. It is a medical condition, not a moral failing.

Physical dependence - A physiological state in which the body adapts to the presence of a drug such that abrupt discontinuation causes withdrawal symptoms. Physical dependence is not the same as addiction.

A patient who takes opioids for months after surgery and experiences withdrawal when stopping is physically dependent; they may or may not have OUD.

Fentanyl - A synthetic opioid 50 to 100 times more potent than morphine by weight. Pharmaceutical fentanyl is used for anesthesia and severe pain management. Illicitly manufactured fentanyl (IMF) has become the dominant drug in the overdose crisis since approximately 2016.

Because a lethal dose of fentanyl weighs approximately 2 milligrams - less than a few grains of table salt - it can be added to any drug supply invisibly and unpredictably.

Naloxone - A fast-acting opioid antagonist that rapidly reverses opioid overdose by displacing opioids from receptors. Marketed as Narcan and Kloxxado, among other brands. Naloxone has essentially no abuse potential and no effect if opioids are not present.

It is safe to administer even if the cause of unresponsiveness is uncertain. Multiple doses may be needed to reverse fentanyl overdose.

Medication-assisted treatment (MAT) - The use of FDA-approved medications (methadone, buprenorphine, naltrexone) to treat opioid use disorder, typically in combination with counseling. Evidence shows these medications reduce overdose mortality, most strongly for methadone and buprenorphine, reduce illicit drug use, and improve social functioning.

The term MOUD (medications for opioid use disorder) is increasingly preferred as it does not imply the medications are merely an "assist" to treatment.

Harm reduction - A public health approach that aims to reduce the negative consequences of drug use without requiring abstinence. Harm reduction interventions include needle exchange programs, naloxone distribution, fentanyl test strips, and supervised consumption sites.

Deaths of despair - A term coined by economists Anne Case and Angus Deaton to describe rising mortality among middle-aged white Americans without college degrees from suicide, alcohol, and drug overdose - patterns they attributed to deteriorating economic conditions and social dislocation following deindustrialization.

Three Waves of the Opioid Crisis

Total US opioid-involved overdose deaths 1999-2021: more than 645,000 (CDC/NCHS National Vital Statistics System). Fentanyl now present in counterfeit pills, stimulants, and other drugs - users often unaware.

The Three Waves of the Opioid Crisis

The opioid epidemic did not arrive as a single event. It unfolded in distinct, overlapping waves, each driven by different drugs and different dynamics, yet each causally connected to the preceding wave.

Wave 1: Prescription Opioids (1999-2010)

The first wave was pharmaceutical. Beginning in the late 1990s, the combination of aggressive opioid marketing, undertrained physicians, inadequate regulatory oversight, and genuine undertreated pain created conditions for mass opioid dependence.

OxyContin was the most prominent drug in this wave but not the only one: hydrocodone combination products (Vicodin, Lortab), hydromorphone (Dilaudid), and extended-release morphine preparations all contributed.

Pill mills - clinics that dispensed opioids with little or no medical justification - flourished in states with weak prescription monitoring programs, particularly Florida, West Virginia, and Ohio.

In Williamson, West Virginia (population approximately 3,000), two pharmacies dispensed 20.8 million opioid pills over two years. In Mingo County, West Virginia, enough opioids were dispensed to supply every resident with 203 pills per year.

The geographic pattern of the first wave was striking: rural and semi-rural communities, disproportionately white, in regions experiencing economic decline. Appalachia was hit hardest. The overlap between areas of high opioid prescribing and areas of manufacturing job loss was not coincidental.

Whether economic despair caused people to seek opioids, or opioid addiction caused economic deterioration - or both directions simultaneously - became a subject of serious empirical research.

Case and Deaton's 2015 paper in PNAS documented rising mortality among white non-Hispanic Americans aged 45-54, driven by drugs, alcohol, and suicide, and linked this pattern to eroding economic prospects for non-college-educated Americans.

Wave 2: Heroin (2010-2013)

The second wave emerged from supply-side interventions in the prescription drug market. Between 2010 and 2012, several states implemented prescription drug monitoring programs (PDMPs), which allowed pharmacies and prescribers to check whether patients were obtaining opioids from multiple sources.

Purdue reformulated OxyContin in 2010 to an abuse-deterrent version that gelled rather than dissolved when crushed, making it harder to snort or inject. Crackdowns on pill mills in Florida and other states reduced supply.^[3]

For people who had developed severe physical dependence, these supply reductions did not end the problem. They changed the drug. Heroin, which had been driven from many US markets by prescription opioids, returned - cheaper, often purer, and more widely available as Mexican cartels expanded distribution to fill the gap.

A 2014 study in JAMA Psychiatry (Cicero et al.) found that about 75 percent of people entering heroin treatment in the 2000s had started with prescription opioids.^[2] The sequence was clear: prescription drugs first, heroin when prescriptions became unavailable.

Heroin overdose deaths roughly quadrupled between 2010 and 2014. The demographics shifted somewhat - heroin use expanded beyond the urban communities it had historically concentrated in, into suburban and rural areas, reaching populations that had been introduced to opioids through legitimate prescriptions.

Wave 3: Synthetic Opioids and Fentanyl (2013-Present)

The third wave transformed the overdose crisis in ways that have made it dramatically harder to address. Beginning around 2013-2014, illicitly manufactured fentanyl began appearing in the heroin supply.

By around 2016, in a number of U.S. regions much of the heroin supply was found to be fentanyl or fentanyl mixed with heroin, though national market-share figures are uncertain. By 2018, many areas reported that essentially all street opioids were fentanyl or fentanyl analogues.

The public health consequences were profound. Fentanyl's extreme potency means that variation in concentration within a single batch - let alone between batches from different suppliers - can be the difference between a normal dose and a lethal one.

Users who believed they were buying heroin were buying fentanyl, with no reliable way to know the concentration. Counterfeit prescription pills - fake OxyContin, fake Xanax, fake Adderall - began appearing, many containing lethal fentanyl doses.

These pills looked identical to legitimate medications and were being purchased by people who would never have knowingly bought heroin.

Synthetic opioid overdose deaths exceeded 70,000 per year in the United States by 2021.

The geographic and demographic patterns shifted: urban communities of color, which had been somewhat protected during the first wave's prescription drug concentration in rural areas, were disproportionately affected in the fentanyl wave, particularly in the western United States where black tar heroin had historically dominated and where the heroin-to-fentanyl transition happened later but with devastating speed.

Some researchers now describe a fourth wave: the combination of fentanyl with stimulants - cocaine and methamphetamine - either through intentional mixing or contamination. This combination changes the overdose pharmacology.

Naloxone reverses opioid-induced respiratory depression but does not address stimulant-induced cardiac effects. Multiple doses of naloxone are often required.

The Neuroscience of Opioid Addiction

Understanding why opioids are so addictive requires understanding how they interact with the brain's reward and pain systems.

Mu-Opioid Receptors and the Reward Circuit

The brain's endogenous opioid system is ancient and pervasive. The body naturally produces opioid compounds - endorphins, enkephalins, dynorphins - that bind to three types of opioid receptors: mu, kappa, and delta.

The mu-opioid receptor (MOR) is responsible for most of the analgesic effects of opioids, and also for most of their addictive properties.

When an exogenous opioid binds to MORs in the ventral tegmental area (VTA) of the brain, it inhibits GABAergic interneurons - neurons that normally suppress dopamine release.

By inhibiting these inhibitors, opioids disinhibit dopamine neurons, producing a surge of dopamine in the nucleus accumbens (NAc).^[4] This dopamine release encodes the experience as highly rewarding, reinforcing the behavior that produced it.

Natural rewards - food, social connection, sex - produce dopamine responses that peak and then return to baseline. Opioids, particularly fast-acting ones, produce larger and more abrupt dopamine responses that do not follow the same patterns.

Over time, the mesolimbic system adapts: dopamine receptors are downregulated, natural pleasures become less rewarding, and the drug becomes increasingly necessary just to feel normal rather than to feel good.

Tolerance, Dependence, and the Withdrawal Trap

Chronic opioid exposure triggers receptor-level adaptations. Mu-opioid receptors are internalized - pulled into the cell - and the density of surface receptors decreases. The cellular signaling cascades downstream of receptor activation are also downregulated.

The result is tolerance: increasing doses are needed to produce the same effect.

Simultaneously, the body's natural opioid production is suppressed. The hypothalamic-pituitary-adrenal axis, the noradrenergic system in the locus coeruleus, and multiple other systems adapt to the presence of exogenous opioids.

When opioids are removed, these systems are suddenly unopposed - the locus coeruleus fires excessively, producing anxiety, sweating, elevated heart rate, and muscle cramping. The nucleus accumbens, depleted of dopamine, generates intense craving.

Gastrointestinal opioid receptors, suddenly unoccupied, produce diarrhea and cramping. This withdrawal syndrome is experientially agonizing and, while generally not life-threatening in otherwise healthy adults, can be medically serious in higher-risk cases.

The withdrawal trap is a key driver of continued opioid use that is distinct from euphoria-seeking. Many people continue using opioids primarily to avoid withdrawal, not to get high. This distinction matters for treatment: an effective treatment must address withdrawal as well as craving.

Opioid-Induced Hyperalgesia

A paradox of long-term opioid use is that it can increase sensitivity to pain rather than decrease it. Opioid-induced hyperalgesia (OIH) occurs when chronic opioid exposure triggers neuroadaptations - including activation of spinal NMDA receptors and descending pain facilitation systems - that amplify pain signals.

Patients on long-term opioid therapy for chronic pain sometimes experience worsening pain not because their underlying condition has progressed but because the opioids themselves are sensitizing their pain systems. This traps patients in a cycle: pain worsens, dose increases, hyperalgesia intensifies, pain worsens further.

Purdue Pharma, the Sacklers, and the Failure of Regulation

The opioid crisis was not an accident. Internal documents released through litigation - and analyzed by journalists including Patrick Radden Keefe, Beth Macy, and Sam Quinones - reveal a company that systematically misled physicians and regulators about OxyContin's addiction risk.

Purdue's sales training materials instructed representatives to minimize addiction concerns with specific phrases, to counter negative clinical experiences with scripted rebuttals, and to focus detailing efforts on the highest-prescribing physicians - some of whom were clearly operating outside normal practice standards.

The company ran a speaker bureau that paid physicians to give talks promoting OxyContin at dinners and events. Internal tracking data showed that some of Purdue's top prescribers were prescribing in quantities and patterns that should have triggered concern - but those physicians were also the company's highest-volume customers.

The DEA bears substantial responsibility as well. The DEA had authority under the Controlled Substances Act to set production quotas for Schedule II substances and to take enforcement action against distributors shipping suspicious quantities.

Neither authority was exercised effectively during the critical years of the epidemic's growth.

A 2017 investigation by the Washington Post and "60 Minutes" revealed that the DEA's enforcement capacity had been deliberately weakened by a 2016 law - the Ensuring Patient Access and Effective Drug Enforcement Act - that was heavily lobbied by the pharmaceutical distribution industry and passed with bipartisan support.

McKinsey and Company, the consulting firm, paid $573 million in settlements in 2021 after documents revealed it had advised Purdue to pursue strategies to "turbocharge" OxyContin sales during the period from 2004 to 2019 - including a 2017 plan that proposed offering rebates to distributors for each OxyContin overdose, a strategy that documents show was framed as a way to continue profitable distribution even as overdose deaths mounted.

Treatment: What Works

The evidence on opioid use disorder treatment is unusually clear: medications work.^[6] The political resistance to using them has cost lives.

Methadone

Methadone is a long-acting full mu-opioid agonist that, at therapeutic doses, reduces craving and prevents withdrawal without producing euphoria.

More than 50 randomized controlled trials establish methadone maintenance treatment's efficacy and retention benefits; large observational cohorts show it reduces overdose mortality by approximately 50 percent, reduces illicit opioid use, reduces criminal activity associated with drug procurement, and improves social functioning.

Despite this evidence, methadone for OUD can only be dispensed through federally certified opioid treatment programs (OTPs), which operate under heavy regulatory oversight. Patients typically must appear in person daily, at least initially.

OTPs are scarce in rural areas and many urban neighborhoods. In most of the United States, a patient who develops OUD has no way to access methadone without traveling significant distances - a barrier that kills people.

Buprenorphine

Buprenorphine is a partial mu-opioid agonist with high receptor affinity. It reduces cravings and withdrawal and, because it is a partial rather than full agonist, has a ceiling effect on respiratory depression - making it substantially safer than full agonist opioids in overdose.

Suboxone combines buprenorphine with naloxone in a formulation designed to deter injection.

Buprenorphine can be prescribed in office-based settings by any eligible DEA-registered practitioner (including nurse practitioners and physician assistants, within state-law scope) - since the elimination of the DEA's X-waiver requirement in late 2022 - but significant barriers remain, including pharmacy reluctance to stock it, prior authorization requirements from insurers, and lack of prescriber training and willingness.

Naltrexone

Naltrexone, a full opioid antagonist, blocks the effects of opioids entirely. The extended-release injectable form (Vivitrol) has the advantage of not requiring daily adherence.

The disadvantage is that it requires complete detoxification before initiation - a high hurdle - and shows consistently lower retention rates than agonist therapies.

For patients who prefer abstinence-based approaches or are in settings where agonist therapy is unavailable (such as some correctional facilities), naltrexone offers benefit.

Harm Reduction: The Evidence

Harm reduction is not ideological compromise - it is evidence-based public health. Needle exchange programs reduce HIV and hepatitis C transmission without increasing drug use. Naloxone distribution to people who use drugs, their families, and community members prevents overdose deaths.

Fentanyl test strips provide information that allows people to make more informed decisions about what they are using.

Supervised consumption sites - facilities where people bring their own drugs and use them under medical supervision, without risk of arrest - have operated for decades in Canada, Switzerland, the Netherlands, Germany, and Australia. The evidence is consistent: they save lives without increasing drug use in surrounding communities.

Vancouver's Insite opened in 2003; a 2011 Lancet study found a 35 percent reduction in overdose mortality in the surrounding area.^[5]

Long-running supervised consumption sites such as Insite in Vancouver, which opened in 2003, have documented no on-site overdose deaths in that time. The first officially sanctioned supervised consumption sites in the United States, operated by OnPoint NYC in Washington Heights and East Harlem, began operating on November 30, 2021.

The political obstacles to harm reduction have no public health justification. They reflect the persistence of an abstinence-only ideology that treats drug use as a moral failure to be punished rather than a health condition to be managed. The cost of this ideology, measured in deaths, is large.

Geography, Despair, and Structural Vulnerability

The opioid crisis is not distributed randomly. Its first waves concentrated heavily in Appalachia, the rural Midwest, and other regions that experienced deindustrialization - the loss of manufacturing employment that had provided stable working-class livelihoods.

Towns where coal mines closed, steel mills shuttered, or manufacturing plants moved experienced not just income loss but the collapse of the entire social infrastructure that paid employment had supported.

Anne Case and Angus Deaton, in a paper published in PNAS in 2015, documented a remarkable pattern: rising all-cause mortality among non-Hispanic white Americans aged 45-54 without college degrees, driven almost entirely by drug overdose, alcohol-related liver disease, and suicide.^[1]

This diverged sharply from trends in other wealthy countries and from trends among other American demographic groups.

They called these "deaths of despair" - mortality driven not by the traditional risk factors of poverty and poor health care access but by the deterioration of the life prospects, social connections, and sense of purpose that stable employment and community provided.

The relationship between despair and vulnerability to opioids is not simply that desperate people seek drugs. It is that opioids are particularly effective at temporarily alleviating the specific psychological profile of social pain - social exclusion, loss of status, grief - through the same receptor systems involved in physical pain.

Research by Naomi Eisenberger and others has shown that opioid receptors mediate social bonding and social pain as well as physical pain.

For people experiencing profound social loss, opioids may be, in a neurobiological sense, precisely targeted medicine for their suffering.

For more on how social conditions shape addiction risk, see how addiction works and how inequality affects health. For a broader framework of poverty and vulnerability, see how poverty traps work.

The Ongoing Crisis

The opioid epidemic has not ended. Overdose deaths exceeded 80,000 per year in the United States in 2021 and 2022 - a figure that reflects the full severity of the fentanyl era.

Progress on the structural front has been significant: pharmaceutical settlements have directed billions toward treatment and harm reduction, the X-waiver has been eliminated, naloxone is available over the counter, and fentanyl test strips are legal in most states.

But the supply of illicitly manufactured fentanyl - and increasingly fentanyl analogues and novel synthetic opioids - continues to expand, driven by global chemical supply chains that have proven resistant to interdiction.

Without a substantial expansion of treatment access, harm reduction infrastructure, and the social conditions that make recovery sustainable, the mortality will continue.

The opioid crisis is a story about pharmaceutical misconduct, regulatory failure, and political dysfunction. It is also a story about pain - physical and social - and about what happens when the systems designed to address pain are corrupted into instruments of profit.

Sources & Further Reading

1. Case, A., & Deaton, A. (2015). Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. PNAS, 112(49), 15078-15083. DOI: 10.1073/pnas.1518393112
2. Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). The changing face of heroin use in the United States. JAMA Psychiatry, 71(7), 821-826. DOI: 10.1001/jamapsychiatry.2014.366
3. Kennedy-Hendricks, A., et al. (2016). Opioid overdose deaths and Florida's crackdown on pill mills. American Journal of Public Health, 106(2), 291-297. DOI: 10.2105/AJPH.2015.302953
4. Kreek, M. J., Levran, O., Reed, B., Schlussman, S. D., Zhou, Y., & Butelman, E. R. (2012). Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. Journal of Clinical Investigation, 122(10), 3387-3393. DOI: 10.1172/JCI60390
5. Milloy, M.-J., et al. (2008). Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility. The Lancet, 367(9522), 1055-1060. DOI: 10.1016/S0140-6736(06)68456-5
6. Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019). Prevention and treatment of opioid misuse and addiction. JAMA Psychiatry, 76(2), 208-216. DOI: 10.1001/jamapsychiatry.2018.3126

Further Reading

• Gomes, T., et al. (2011). Opioid dose and drug-related mortality in patients with nonmalignant pain. Archives of Internal Medicine, 171(7), 686-691. DOI: 10.1001/archinternmed.2011.117